This classification system is widely used to guide individual systematic therapy of breast cancer: HR+ patients require effective endocrine therapy; HER2+ patients require anti-HER2 therapy; TNBC patients require cytotoxic therapy. Here, ERBB2 is linked to breast carcinoma.